Alector (ALEC) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Alector (ALEC) overview

Alector (ALEC) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 21.0m and operating profit of USD -156m; the year-end share price was 1.56 USD and market capitalisation was USD 172m. Alector is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Alector's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 30.6mFY 2025
Share price1.56 USDFY 2025 year end
RevenueUSD 21.0mFY 2025
Operating profitUSD -156mFY 2025
Net earningsUSD -143mFY 2025
Market capitalisationUSD 172mFY 2025 year end

About Alector

Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its programs include an investigational antibody designed to elevate progranulin levels and preclinical candidates targeting Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia. The company is also developing a blood-brain barrier delivery platform intended to support delivery of antibodies, enzymes, proteins, and siRNA to the brain.

Generate the Alector report

Alector is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Alector and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Alector

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.